SCHEDULE 13G/A: ARK Investment Management Discloses 10.51% Stake in CRISPR Therapeutics AG

ARK Investment Management LLC has filed an amended Schedule 13G, revealing a 10.51% beneficial ownership stake in CRISPR Therapeutics AG as of December 31, 2024.

Summary

• ARK Investment Management LLC reported beneficial ownership of 8,973,063 shares of Common Stock in CRISPR Therapeutics AG.
• This ownership represents 10.51% of the total class of securities outstanding.
• The filing, an Amendment No. 10 to Schedule 13G, was made on February 14, 2025, reflecting the ownership position as of December 31, 2024.
• ARK Investment Management LLC holds sole voting power over 8,435,238 shares and shared voting power over 193,367 shares.
• The firm also holds sole dispositive power over 8,973,063 shares and no shared dispositive power.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a 10.51% beneficial ownership by ARK Investment Management LLC, a well-known investment firm focused on disruptive technologies, suggests a strong vote of confidence in CRISPR Therapeutics AG. While a 13G is a compliance filing, the substantial stake from such an investor can be interpreted positively by the market.

Positives

• A significant stake of 10.51% by a prominent investment manager like ARK Investment Management LLC could be viewed as a vote of confidence in CRISPR Therapeutics AG's long-term prospects.
• The filing indicates that ARK Investment Management LLC holds the shares in the ordinary course of business, not for control purposes, which suggests a focus on investment returns rather than activist intentions.

Future Outlook

NA

Industry Context

This filing indicates continued or increased interest from a major investment firm, ARK Investment Management LLC, in the biotechnology sector, specifically in gene-editing companies like CRISPR Therapeutics AG. ARK is known for its focus on disruptive innovation, suggesting a positive long-term view on the potential of CRISPR technology within the broader biotech landscape.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a prominent investment firm like ARK Investment Management LLC may influence investor sentiment and potentially the stock price, signaling institutional confidence.
• Potential Investors: Provides transparency regarding major institutional holdings, which can be a factor in investment decisions.

Key Dates

Keywords

CRISPR Therapeutics AG, ARK Investment Management LLC, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Gene Editing, Investment Adviser, SEC Filing